Alzheimer's and Parkinson's Spurred by Same Enzyme

Alzheimer's disease and Parkinson's disease affect different regions of the brain and have distinct genetic and environmental risk factors.They are not the same.

But at the biochemical level, these two neurodegenerative diseases start to look similar. That's how Emory scientists led by Keqiang Ye, PhD, landed on a potential drug target for Parkinson's.

Diseases Related to Old Age
Ageing is referred to the accumulation of changes that brings a person closer to death.

‘In control brain samples AEP was confined to lysosomes, parts of the cell with a garbage disposal function.’

In both Alzheimer's (AD) and Parkinson's (PD), a sticky protein forms toxic clumps in brain cells. In AD, the troublemaker inside cells is called tau, making up neurofibrillary tangles. In PD, the sticky protein is alpha-synuclein, forming Lewy bodies.

Ye and his colleagues had previously identified an enzyme (asparagine endopeptidase or AEP) that trims tau in a way that makes it more sticky and toxic. Drugs that inhibit AEP have beneficial effects in Alzheimer's animal models.

In a new Nature Structural and Molecular Biology paper, Emory researchers show that AEP acts in the same way toward alpha-synuclein.

Modified Atkins Diet: All You Need to Know
Modified Atkins diet designed for weight loss and to treat seizures is high in fat and low in carbohydrates. Discover how this diet is different from the ketogenic diet.

"In Parkinson's, alpha-synuclein behaves much like Tau in Alzheimer's," Ye says. "We reasoned that if AEP cuts Tau, it's very likely that it will cut alpha-synuclein too."

A particular chunk of alpha-synuclein produced by AEP's scissors can be found in samples of brain tissue from patients with PD, but not in control samples, Ye's team found.

First Case of Alzheimer�s Diagnosed in a HIV-Positive Patient
Chronic HIV infection and amyloid deposition with aging may represent a double-hit to the brain that results in progressive dementia.

But in PD samples, AEP was leaking out of the lysosomes to the rest of the cell.

The researchers also observed that the chunk of alpha-synuclein generated by AEP is more likely to aggregate into clumps than the full length protein, and is more toxic when introduced into cells or mouse brains. In addition, alpha-synuclein mutated so that AEP can't cut it is less toxic.

Mice Breed Used In Alzheimer�s Disease Research Not That Effective
Scientists opine that recently developed mouse breeds that mimic the symptoms of Alzheimer's disease.

Ye cautions that AEP is not the only enzyme that cuts alpha-synuclein into various toxic pieces, and the full-length alpha-synuclein protein is still able to aggregate and cause harm. Nevertheless, he says his team is moving on to testing drugs that inhibit AEP in Parkinson's animal models.

Source-Eurekalert